3i Biotech
Why gingival delivery?
Illustrative demo onlyJunctional Epithelium (JE) as a gateway
The JE within the gingival crevice is highly permeable, making it a compelling site for systemic and mucosal delivery of medicaments. 3i devices place drug payloads precisely at this interface for efficient uptake.
Values are illustrative to communicate the concept; not clinical measurements.
Innovative Dental Devices
Drug‑coated floss & floss picks engineered for delivery into the gingival crevice—targeting the junctional epithelium (JE).
Oral Microneedle Platforms
Novel coatings and applicators designed for precise, minimally invasive dosing within the oral cavity.
Vitamins, Biologics & Vaccines
Supports delivery of micronutrients and vaccine candidates directly to permeable oral tissues.
Targeted Patient Populations
Designed for needs of post‑bariatric patients where upper‑GI absorption is impaired—helping mitigate risks like Wernicke’s encephalopathy.
Addressing post‑bariatric supplementation
Bariatric procedures alter the upper gastrointestinal tract, which can reduce absorption of essential vitamins and micronutrients. Without supplementation, patients may face serious complications—including neurological conditions such as Wernicke’s encephalopathy. 3i’s coated floss and floss picks are designed to deliver micronutrients directly to permeable oral tissues, bypassing upper‑GI limitations.
Patients with reduced upper‑GI absorption require reliable supplementation strategies. Gingival delivery offers a local‑to‑systemic bridge.
Designed for adherence
Familiar dental tools with embedded therapeutics can fit seamlessly into daily routines.
Precision placement
Payloads concentrated at the JE within the gingival crevice maximize exposure to permeable tissues.
Publication Spotlight
Listen to a discussion on Dr. Rohan Ingrole's recent publication in Nature Biomedical Engineering, "Floss-based vaccination targets the gingival sulcus for mucosal and systemic immunization."
Founders’ Publications
Peer‑reviewed work by our founders in drug delivery, bariatric nutrition, and molecular messaging.
Seth Boese, PhD
- Drug coated microneedles for minimally-invasive treatment of oral carcinomas: development and in vitro evaluation
- Coated floss for drug delivery into the gum pocket
- Drug‑Coated Floss to Treat Gum Diseases: In Vitro and In Vivo Characterization
- Coated dental floss as a novel instrument for drug delivery to the Gingival Mucosa: Development, characterization, and In vivo delivery
Rohan Ingrole, PhD
- Floss‑based vaccination targets the gingival sulcus for mucosal and systemic immunization
- Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses
- Trends of microneedle technology in the scientific literature, patents, clinical trials and internet activity
- Microneedle Coating Methods: A Review with a Perspective
David Syn, MD
- Galyean S, Syn D, Subih HS, Boylan M. Improving vitamin D status in bariatric surgery subjects with monthly high-dose ergocalciferol.
- Goktas Z, Owens S, Boylan M, Syn D, Shen CL, Reed DB, San Francisco S, Wang S. Associations between tissue visfatin/nicotinamide, phosphoribosyltransferase (Nampt), retinol binding protein-4, and vaspin concentrations and insulin resistance in morbidly obese subjects.
- Tilson MD, Fu C, Xia SX, Syn D, Yoon Y, McCaffrey T. Expression of molecular messages for angiogenesis by fibroblasts from aneurysmal abdominal aorta versus dermal fibroblasts.
- Solomon AJ, Syn D, Barbey JT. A simple in vivo model to evaluate the effects of antiarrhythmic agents.
Full bibliographic details available upon request.
A multidisciplinary team
3i Biotech brings together physicians, surgeons, scientists, and attorneys to translate cutting‑edge research into practical, compliant devices that improve patient outcomes.
Our devices include coated floss and floss picks, oral microneedles, and other instruments that target the gingival crevice—especially the junctional epithelium—for efficient absorption of vitamins, supplements, and potential vaccine candidates.
Intellectual Property
3i is innovating across multiple device classes with a robust and growing IP portfolio—currently 0+ patent applications pending.
Partners & Collaborations
We collaborate with academic and clinical teams to validate delivery performance and explore new indications.
Let’s build together
Interested in co‑development, clinical validation, or licensing? Reach out and we’ll follow up with next steps.
Use the button above or email info@3ibiotech.com